Measures of disease activity and severity at baseline and 24-month follow-up compared across serology status
| Measure | Baseline | 24 months | Δ0–24 months | ||||||
| Seronegative (n=34) | Seropositive (n=196) | P values | Seronegative (n=34) | Seropositive (n=196) | P values | Seronegative (n=34) | Seropositive (n=196) | P values | |
| DAS* | 3.9 (1.2) | 3.4 (1.2) | 0.029 | 1.2 (0.9) | 1.3 (0.9) | 0.40 | −2.7 (1.3) | −2.1 (1.2) | 0.007 |
| 44-SJC | 18 (11 to 25) | 8 (4 to 13) | < 0.001 | 0 (0 to 0) | 0 (0 to 1) | 0.73 | −17 (-23 to 11) | −7 (–13 to 4) | < 0.001 |
| CRP | 7 (3 to 27) | 7 (3 to 18) | 0.50 | 3 (1 to 4) | 3 (1 to 5) | 0.42 | −4 (–23 to 0) | −4 (–11 to 0) | 0.50 |
| ESR | 13 (10 to 29) | 21 (12 to 33) | 0.14 | 7 (4 to 12) | 8 (5 to 15) | 0.11 | −7 (-17 to 2) | −8 (-19 to 3) | 0.44 |
| Tender joints† | 7 (3–14) | 7 (4–13) | 0.92 | 0 (0 to 1) | 0 (0 to 2) | 0.57 | −6 (−11 to 2) | −5 (-11–3) | 0.59 |
| Physician Global VAS | 49 (22) | 39 (20) | 0.008 | 7 (9) | 10 (11) | 0.28 | −42 (24) | −29 (22) | 0.003 |
| Patient Global VAS | 50 (27) | 50 (24) | 0.90 | 18 (20) | 18 (22) | 0.996 | −32 (31) | −32 (27) | 0.91 |
| US PD joint score | 13.0 (7.0 to 22.0) | 6.0 (2.0 to 12.5) | < 0.001 | 0.0 (0.0 to 1.0) | 0.0 (0.0 to 0.0) | 0.68 | −11.0 (−22.0 to 5.0) | −6.0 (−11.0 to 2.0) | 0.002 |
| US GS joint score | 33.0 (21.0–51.0) | 17.0 (10.0 to 25.0) | < 0.001 | 3.5 (0.0 to 7.0) | 4.0 (1.0 to 7.0) | 0.73 | −27.0 (−43.0 to 16.0) | −11.5 (−20.0 to 6.0) | < 0.001 |
| Total vdHS score | 5.5 (2.0–13.0) | 4.0 (1.5 to 8.0) | 0.17 | 9.5 (2.5 to 16.0) | 5.5 (3.0 to 10.3) | 0.17 | 1.5 (0.5 to 3.0) | 1.0 (0.0 to 3.0) | 0.36 |
| Joint space narrowing | 1.5 (0.0 to 6.0) | 1.0 (0.0 to 3.0) | 0.047 | 2.5 (1.0 to 7.5) | 1.0 (0.0 to 4.0) | 0.059 | 0 .0 (0.0 to 1.0) | 0.0 (0.0 to 0.5) | 0.31 |
| Erosion score | 3.0 (1.0 to 6.5) | 3.0 (1.0 to 4.5) | 0.42 | 4.0 (2.0 to 9.0) | 4.0 (2.0 to 7.0) | 0.34 | 1.0 (0.5 to 2.0) | 0.7 (0.0 to 2.0) | 0.68 |
| Pain VAS | 44 (25 to 71) | 48 (29 to 70) | 0.58 | 14 (4 to 27) | 8 (2 to 28) | 0.22 | −26 (−51 to 3) | −31 (−50 to 13) | 0.35 |
| Fatigue VAS | 36 (22 to 67) | 38 (14 to 65) | 0.88 | 9 (2 to 38) | 13 (3 to 38) | 0.56 | −21 (−36 to 3) | −13 (−39 to 2) | 0.76 |
| PROMIS Physical | 39.2 (30.1 to 46.0) | 39.3 (33.3 to 44.2) | 0.86 | 51.2 (44.2 to 62.5) | 50.0 (42.6 to 62.5) | 0.50 | 12.3 (6.9 to 18.9) | 11.7 (5.4 to 17.9) | 0.47 |
Bold indicates p<0.05. Values are median (25th–75th percentiles) or mean (SD).
*Original disease activity score based on ESR, patient global, 44-SJC and Ritchie Articular Index.
†Assessed by Ritchie Articular Index.
CRP, C reactive protein (mg/L); DAS, disease activity score; ESR, erythrocyte sedimentation rate (mm/hour); PROMIS, Patient-Reported Outcome Measurement Information System; SJC, swollen joint count; US GS, Ultrasound Grey Scale; US PD, ultrasound power Doppler; VAS, visual analogue scale (0–100 mm); vdHS, van der Heijde modified Sharp.